Literature DB >> 1826326

Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.

P Vieregge1, G Ziemens, M Freudenberg, A Piosinski, A Muysers, B Schulze.   

Abstract

Extrapyramidal, frontal release, and other neurological signs were studied in 54 demented and non-demented patients with Down's syndrome (DS). Fourteen patients were demented and five showed extrapyramidal signs, mainly of the rigid-hypokinetic spectrum and similar to Parkinsonian features in advanced Alzheimer's disease (AD). None of the non-demented patients had Parkinsonian signs. The mean age of the demented DS patients with extrapyramidal signs was significantly higher than that of the patients without. Frontal release signs were present in demented and non-demented patients. A questionnaire showed no increase in either the proportion of early- or senile-onset dementia or Parkinsonism among first- and second-degree relatives of DS patients. Parkinsonian signs appear to be present at a lower frequency in DS than in advanced AD. A speculative hypothesis about a gene dosage effect of Cu/Zn-superoxide dismutase in preventing toxic radical formation in the substantia nigra of DS patients is presented.

Entities:  

Mesh:

Year:  1991        PMID: 1826326      PMCID: PMC1014295          DOI: 10.1136/jnnp.54.1.34

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  48 in total

1.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome.

Authors:  C J Epstein; K B Avraham; M Lovett; S Smith; O Elroy-Stein; G Rotman; C Bry; Y Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Down's syndrome and its association with Alzheimer's disease.

Authors:  L N Yatham; P A McHale; A Kinsella
Journal:  Acta Psychiatr Scand       Date:  1988-01       Impact factor: 6.392

3.  Parkinson's disease in patients with Alzheimer's disease.

Authors:  J Leverenz; S M Sumi
Journal:  Arch Neurol       Date:  1986-07

4.  Clinical subtypes of dementia of the Alzheimer type.

Authors:  H C Chui; E L Teng; V W Henderson; A C Moy
Journal:  Neurology       Date:  1985-11       Impact factor: 9.910

5.  Alzheimer's disease in Down's syndrome: clinicopathologic studies.

Authors:  K E Wisniewski; A J Dalton; C McLachlan; G Y Wen; H M Wisniewski
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

6.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.

Authors:  K E Wisniewski; H M Wisniewski; G Y Wen
Journal:  Ann Neurol       Date:  1985-03       Impact factor: 10.422

7.  Heterogeneity in dementia of the Alzheimer type: evidence of subgroups.

Authors:  R Mayeux; Y Stern; S Spanton
Journal:  Neurology       Date:  1985-04       Impact factor: 9.910

8.  A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.

Authors:  H Saggu; J Cooksey; D Dexter; F R Wells; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-09       Impact factor: 5.372

9.  Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus.

Authors:  R J Marttila; H Lorentz; U K Rinne
Journal:  J Neurol Sci       Date:  1988-09       Impact factor: 3.181

10.  Motor signs are infrequent in dementia of the Alzheimer type.

Authors:  W C Koller; R S Wilson; S L Glatt; J H Fox
Journal:  Ann Neurol       Date:  1984-10       Impact factor: 10.422

View more
  5 in total

1.  Selective loss of nigral neurons in Alzheimer's disease: a morphometric study.

Authors:  T Uchihara; H Kondo; K Kosaka; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Down's syndrome and Parkinson's disease.

Authors:  A Hestnes; S E Daniel; A J Lees; A Brun
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

Review 3.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

4.  DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.

Authors:  M J Barallobre; C Perier; J Bové; A Laguna; J M Delabar; M Vila; M L Arbonés
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

5.  Levodopa-Responsive Early-Onset Parkinsonism in Down Syndrome.

Authors:  Padmini Palat; Francis Hickey; Lina Patel; Elise Sannar
Journal:  Case Rep Neurol Med       Date:  2018-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.